Activation of Eosinophils Interacting with Dermal Fibroblasts by Pruritogenic Cytokine IL-31 and Alarmin IL-33: Implications in Atopic Dermatitis

Background IL-31 is a pruritogenic cytokine, and IL-33 is an alarmin for damaging inflammation. They together relate to the pathogenesis of atopic dermatitis (AD). Eosinophil infiltration into the inner dermal compartment is a predominant pathological feature of AD. We herein investigated the in vitro inflammatory effects of IL-31 and IL-33 on the activation of human eosinophils and dermal fibroblasts. Methodology/Principal Findings Receptors, adhesion molecules and signaling molecules were assessed by Western blot or flow cytometry. Chemokines and cytokine were quantitated by multiplex assay. Functional IL-31 receptor component IL-31RA, OSMR-β and IL-33 receptor component ST2 were constitutively expressed on the surface of eosinophils. Co-culture of eosinophils and fibroblasts significantly induced pro-inflammatory cytokine IL-6 and AD-related chemokines CXCL1, CXCL10, CCL2 and CCL5. Such inductions were further enhanced with IL-31 and IL-33 stimulation. IL-31 and IL-33 could significantly provoke the release of CXCL8 from eosinophils and fibroblasts, respectively, which was further enhanced upon co-culture. In co-culture, eosinophils and fibroblasts were the main source for the release of CCL5, and IL-6, CXCL1, CXCL8, CXCL10 and CCL2, respectively. Direct interaction between eosinophils and fibroblasts was required for CXCL1, CXCL10, CXCL8 and CCL5 release. Cell surface expression of intercellular adhesion molecule-1 on eosinophils and fibroblasts was up-regulated in co-culture upon IL-31 and IL-33 stimulation. The interaction between eosinophils and fibroblasts under IL-31 and IL-33 stimulation differentially activated extracellular signal-regulated kinase, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase, nuclear factor-κB and phosphatidylinositol 3-kinase–Akt pathways. Using specific signaling molecule inhibitors, the differential induction of IL-31 and IL-33-mediated release of cytokines and chemokines such as IL-6 and CXCL8 from co-culture should be related to their distinct activation profile of intracellular signaling pathways. Conclusions/Significance The above findings suggest a crucial immunopathological role of IL-31 and IL-33 in AD through the activation of eosinophils-fibroblasts interaction via differential intracellular signaling mechanisms.

[1]  B. Lüscher,et al.  IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis. , 2012, Acta dermato-venereologica.

[2]  L. French,et al.  Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection. , 2011, The Journal of allergy and clinical immunology.

[3]  T. Werfel,et al.  Functional effects of interleukin 31 in human primary keratinocytes , 2011, Allergy.

[4]  H. Shimizu,et al.  Macrophage migration inhibitory factor is essential for eosinophil recruitment in allergen-induced skin inflammation. , 2011, The Journal of investigative dermatology.

[5]  Y. Gho,et al.  Extracellular vesicles derived from Staphylococcus aureus induce atopic dermatitis-like skin inflammation , 2011, Allergy.

[6]  R. Lafyatis,et al.  dsRNA activation of endothelin-1 and markers of vascular activation in endothelial cells and fibroblasts , 2010, Annals of the rheumatic diseases.

[7]  C. Lam,et al.  Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis. , 2010, International immunology.

[8]  I. McInnes,et al.  Disease-associated functions of IL-33: the new kid in the IL-1 family , 2010, Nature Reviews Immunology.

[9]  C. Wong,et al.  Intracellular signaling mechanisms regulating the activation of human eosinophils by the novel Th2 cytokine IL-33: implications for allergic inflammation , 2010, Cellular and Molecular Immunology.

[10]  Miran Kim,et al.  IL-6, VEGF, KC and RANTES are a major cause of a high irritant dermatitis to phthalic anhydride in C57BL/6 inbred mice. , 2010, Allergology international : official journal of the Japanese Society of Allergology.

[11]  R. Locksley,et al.  IL‐18 and IL‐33 elicit Th2 cytokines from basophils via a MyD88‐ and p38α‐dependent pathway , 2009, Journal of leukocyte biology.

[12]  F. Liew,et al.  The cytokine interleukin-33 mediates anaphylactic shock , 2009, Proceedings of the National Academy of Sciences.

[13]  C. Dahinden,et al.  Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. , 2009, Blood.

[14]  K. Matsushima,et al.  Anti‐interleukin‐31‐antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis , 2009, Experimental dermatology.

[15]  M. Teixeira,et al.  IL-33 Induces Antigen-Specific IL-5+ T Cells and Promotes Allergic-Induced Airway Inflammation Independent of IL-41 , 2008, The Journal of Immunology.

[16]  S. Ständer,et al.  Correlation of IL-31 serum levels with severity of atopic dermatitis. , 2008, The Journal of allergy and clinical immunology.

[17]  K. Huntoon,et al.  Regulated expression of the IL-31 receptor in bronchial and alveolar epithelial cells, pulmonary fibroblasts, and pulmonary macrophages. , 2008, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[18]  C. Wong,et al.  Molecular Mechanisms of Cytokine and Chemokine Release from Eosinophils Activated by IL-17A, IL-17F, and IL-23: Implication for Th17 Lymphocytes-Mediated Allergic Inflammation , 2008, The Journal of Immunology.

[19]  Songhee Jeon,et al.  Impaired PI3K/Akt Activation-Mediated NF-κB Inactivation Under Elevated TNF-α Is More Vulnerable to Apoptosis in Vitiliginous Keratinocytes , 2007 .

[20]  C. Wong,et al.  Leptin‐mediated cytokine release and migration of eosinophils: Implications for immunopathophysiology of allergic inflammation , 2007, European journal of immunology.

[21]  S. Watanabe,et al.  Leukotriene B4 enhances tumour necrosis factor‐α‐induced CCL27 production in human keratinocytes , 2007 .

[22]  C. Wong,et al.  Intracellular signaling mechanisms regulating toll-like receptor-mediated activation of eosinophils. , 2007, American journal of respiratory cell and molecular biology.

[23]  S. Rose-John,et al.  Interleukin-31 and Oncostatin-M Mediate Distinct Signaling Reactions and Response Patterns in Lung Epithelial Cells* , 2007, Journal of Biological Chemistry.

[24]  Songhee Jeon,et al.  Impaired PI3K/Akt activation-mediated NF-kappaB inactivation under elevated TNF-alpha is more vulnerable to apoptosis in vitiliginous keratinocytes. , 2007, The Journal of investigative dermatology.

[25]  S. Watanabe,et al.  Leukotriene B(4) enhances tumour necrosis factor-alpha-induced CCL27 production in human keratinocytes. , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[26]  C. Capristo,et al.  Immune dysregulation in atopic dermatitis. , 2006, Allergy and asthma proceedings.

[27]  W. Silny,et al.  Selected eosinophil proteins as markers of inflammation in atopic dermatitis patients. , 2006, Acta dermatovenerologica Croatica : ADC.

[28]  A. Bosio,et al.  Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. , 2006, The Journal of allergy and clinical immunology.

[29]  M. Steinhoff,et al.  Cytokines and chemokines orchestrate atopic skin inflammation. , 2006, The Journal of allergy and clinical immunology.

[30]  S. Nakaike,et al.  Involvement of IL‐31 on scratching behavior in NC/Nga mice with atopic‐like dermatitis , 2006, Experimental dermatology.

[31]  M. Steinhoff,et al.  IL-31: a new link between T cells and pruritus in atopic skin inflammation. , 2006, The Journal of allergy and clinical immunology.

[32]  B. Harder,et al.  IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. , 2006, The Journal of allergy and clinical immunology.

[33]  J Fernando Bazan,et al.  IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. , 2005, Immunity.

[34]  G. Girolomoni,et al.  ERK1/2 Regulates Epidermal Chemokine Expression and Skin Inflammation1 , 2005, The Journal of Immunology.

[35]  S. Chevalier,et al.  Predominant expression of the long isoform of GP130-like (GPL) receptor is required for interleukin-31 signaling. , 2004, European cytokine network.

[36]  P. Heinrich,et al.  Characterization of the Signaling Capacities of the Novel gp130-like Cytokine Receptor* , 2004, Journal of Biological Chemistry.

[37]  Scott R. Presnell,et al.  Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice , 2004, Nature Immunology.

[38]  H. Simon,et al.  Eosinophils and atopic dermatitis , 2004, Allergy.

[39]  A. Wardlaw Eosinophil trafficking: new answers to old questions , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[40]  C. Wong,et al.  Clinical applications of cytokine assays. , 2003, Advances in clinical chemistry.

[41]  V. Rutten,et al.  Immune dysregulation in atopic dermatitis. , 2002, Veterinary immunology and immunopathology.

[42]  A. Kapp,et al.  Tissue eosinophilia in acute and chronic atopic dermatitis: a morphometric approach using quantitative image analysis of immunostaining , 2001, The British journal of dermatology.

[43]  S. Taniuchi,et al.  Serum eosinophil derived neurotoxin may reflect more strongly disease severity in childhood atopic dermatitis than eosinophil cationic protein. , 2001, Journal of dermatological science.

[44]  P. Conti,et al.  MCP-1 and RANTES are mediators of acute and chronic inflammation. , 2001, Allergy and asthma proceedings.

[45]  A. Zlotnik,et al.  The biology of chemokines and their receptors. , 2000, Annual review of immunology.

[46]  J. Schröder,et al.  The Role of Chemokines in Cutaneous Allergic Inflammation , 1999, Biological chemistry.

[47]  K. Nishioka [Clinical practice of atopic dermatitis]. , 1997, Arerugi = [Allergy].

[48]  P. Askenase,et al.  Development of Atopic Dermatitis-like Skin Lesion with Ige Hyperproduction in Nc/nga Mice , 2022 .

[49]  J. Hanifin,et al.  Increased interleukin 6 production by T cells derived from patients with atopic dermatitis. , 1993, The Journal of investigative dermatology.

[50]  P. Bruijnzeel,et al.  The involvement of eosinophils in the patch test reaction to aeroallergens in atopic dermatitis: its relevance for the pathogenesis of atopic dermatitis , 1993, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[51]  D. C. Fournier,et al.  Interleukin-6 is released in the cutaneous response to allergen challenge in atopic individuals. , 1992, The Journal of allergy and clinical immunology.

[52]  M. Uehara,et al.  Blood eosinophilia in atopic dermatitis , 1990, Clinical and experimental dermatology.

[53]  C. Griffiths,et al.  The role of adhesion molecules, chemotactic factors, and cytokines in inflammatory and neoplastic skin disease--1990 update. , 1990, The Journal of investigative dermatology.

[54]  R. Larson,et al.  Structure and Function of Leukocyte Integrins , 1990, Immunological reviews.